A Sanofi spokesperson told BioSpace in an emailed statement that the company made the strategic decision of focusing on offering the combination therapy Soliqua consisting of GLP-1 and basal insulin to help people manage their diabetes. The spokesperson added that Soliqua has since become one of the cornerstone therapies in its diabetes portfolio and represents an important growth asset for the company
In preclinical models of neurodegeneration, GLP-1R agonists reduce amyloid plaque formation, improve neuronal survival, and reduce neuroinflammation
Established alcohol treatment still sets the clinical standard
List of few ongoing clinical trials involving obesity therapies In short, the future of GLP-1 therapy is moving toward greater convenience, higher efficacy, and more individualized care
Future orders can be canceled anytime through the patient portal
For example, a person with a BMI of 28 and high blood pressure might reach the required medical standard